Peers & Perspectives in Oncology
June II, 2024
June I 2024
May 2024
Volume: 2
Issue: 7
April II, 2024
April I, 2024
March 2024
February II, 2024
Volume: 2
Issue: 3
February I, 2024
Volume: 2
Issue: 2
January 2024
Volume: 2
Issue: 1
December II, 2023
Volume: 1
Issue: 11
December I, 2023
Volume: 1
Issue: 10
November II, 2023
Volume: 1
Issue: 9
November I, 2023
Volume: 1
Issue: 8
October II 2023
Volume: 1
Issue: 7
October I 2023
Volume: 1
Issue: 6
September 2023
Volume: 1
Issue: 5
August 2023
Volume: 1
Issue: 4
July II 2023
Volume: 1
Issue: 3
July I 2023
Volume: 1
Issue: 2
June 2023
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
2
Considering Immunotherapy Rechallenge and TILs for Recurrent Mucosal Melanoma
3
B7-H3–Targeted ADC Risvutatug Rezetecan Extends Survival in Small Cell Lung Cancer
4
FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Tumors
5